IN THE NEWS
Discover the latest insight in these articles featuring inThought analysts and executives:
Is biopharma slowly cracking the code on Alzheimer’s disease? Leon Henderson-MacLennan, M.D., of inThought Research, joins Marc Iskowitz, editor-at-large for MM+M, to explain why January was a pivotal month in neuroscience and why marketers should watch this space.
As drug developers swim hard and fast to neutralize COVID-19 with vaccines and therapeutics, they are also working to get other important drugs approved amid looming threats of halts and delays. 2021 is looking to be a big year for the pharma pipeline.
Biogen’s quest to get a long-awaited new Alzheimer’s drug to market took yet another twist on Friday afternoon as the FDA advisory committee (AdCom) issued an unfavorable vote on recommending the drug for approval.
inDemic announces the launch of its COVID-19 knowledge management system. inDemic’s initial focus is on COVID-19 therapies and vaccines. The site provides in-depth news and analysis of therapies that are being tested to treat COVID-19.
Bloomberg Intelligence and inThought will host a call with immunology experts to discuss development of a Covid-19 therapy and how best to interpret clinical data once they begin to emerge.
Bloomberg Intelligence healthcare analysts and inThought Research experts share their views on the prospects for developing a vaccine against the novel coronavirus.
inThought Research president Ben Weintraub discusses drugs re-emerging from “R&D purgatory” with MM&M.
inThought Research analyst Michelle Rivera speaks with MM&M about the pathophysiology of the disease spinal muscular atrophy (SMA), the SMA drug pipeline, and how payers may react expensive drugs.
Are today’s developmental drugs tomorrow’s blockbusters? MM&M surveys what’s ahead for top candidates in six therapeutic categories.
With less than 14% of Phase I to III drug candidates winning FDA approval, unforeseen roadblocks can derail even the most promising clinical research programs.